Yao mingbio won IPO award and Investor Relations Award

[chinapharma.com Enterprise News] on January 9, 2018, pharmaceutical bio, a global open biopharmaceutical technology platform company that provides customers with end-to-end solutions for discovery, development and production of biopharmaceuticals, announced that it has won the "2017 China financing Award" best IPO award and the best Investor Relations Award of the year The 2017 China financing award ceremony was held in Hong Kong yesterday, in recognition of the outstanding listed companies and financial institutions in 2017 More than 100 executives of listed companies, representatives of financial institutions, celebrities and elites of political and business circles were invited to attend and participate in the event "China financing Award" is held by China financing, a financial magazine It is a grand event in Hong Kong's capital market and one of the important selection activities in the financial industry Since its establishment, the award has been widely concerned and highly recognized by all walks of life in Hong Kong by virtue of the fairness and fairness of the evaluation mechanism and the nature of the evaluation committee The "China financing Award" aims to enhance the brand influence and reputation of enterprises and institutions in the global capital market, deepen the attention and understanding of investors at home and abroad, promote the in-depth communication with investors, show the value of enterprises, and improve the attention of enterprises, so as to promote the economic communication and development between China and Hong Kong, as well as the interconnection of capital markets at home and abroad Since its landing in Hong Kong's capital market in June 2017, Yaoming biology has attracted the attention of investors at home and abroad The two awards are highly recognized for the company's excellent performance in the capital market and the maintenance of investor relations They affirm the company's efforts to increase transparency and strengthen communication with the capital market, and once again reflect the company's brand influence and reputation in the capital market As a Hong Kong listed company, Yaoming bio is a global open, integrated biopharmaceutical capability and technology platform The company provides end-to-end R & D services for global biopharmaceutical companies and biotechnology companies to help anyone and any company discover, develop and produce biopharmaceuticals, realize the whole process from concept to commercial production, accelerate the global R & D process of biopharmaceuticals, reduce R & D costs and benefit patients Original title: Yaoming biology won the 2017 best IPO award and the best Investor Relations Award